BYSI vs. MGTA, MEIP, KMDA, INZY, XOMA, AMRN, ALXO, MGNX, NKTX, and ENTA
Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Magenta Therapeutics (MGTA), MEI Pharma (MEIP), Kamada (KMDA), Inozyme Pharma (INZY), XOMA (XOMA), Amarin (AMRN), ALX Oncology (ALXO), MacroGenics (MGNX), Nkarta (NKTX), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "medical" sector.
BeyondSpring (NASDAQ:BYSI) and Magenta Therapeutics (NASDAQ:MGTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
BeyondSpring received 28 more outperform votes than Magenta Therapeutics when rated by MarketBeat users. Likewise, 66.79% of users gave BeyondSpring an outperform vote while only 57.09% of users gave Magenta Therapeutics an outperform vote.
BeyondSpring's return on equity of 0.00% beat Magenta Therapeutics' return on equity.
BeyondSpring has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Magenta Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.
BeyondSpring has higher revenue and earnings than Magenta Therapeutics.
40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 47.5% of Magenta Therapeutics shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 15.2% of Magenta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Magenta Therapeutics had 2 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Magenta Therapeutics and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.17 beat Magenta Therapeutics' score of 0.95 indicating that BeyondSpring is being referred to more favorably in the media.
Summary
BeyondSpring beats Magenta Therapeutics on 8 of the 11 factors compared between the two stocks.
Get BeyondSpring News Delivered to You Automatically
Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BeyondSpring Competitors List
Related Companies and Tools
